Intensive statin therapy: A favorable adjunct to the improvement of small-diameter vascular grafts

Angiology

Volumn 61, Issue 5, 2010, Pages 427-436

  Li, Jie ^a   Lu, Wei Ming ^a   Li, Xiao Xi ^a   Wang, Shen Ming ^a   Yu, Jian Xing ^a   Zhu, Yi Fan ^a   Liu, Da Yue ^a   Huang, Ming Qing ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

3 hydroxy 3 methylglutaryl (HMG) CoA reductase inhibitors (statins); endothelial progenitor cells; small diameter vascular graft

Indexed keywords

ATORVASTATIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; POLITEF; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA GRAFT; ARTICLE; BLOOD VESSEL DIAMETER; CELL ADHESION; CELL MIGRATION; CONTROLLED STUDY; DOG; DOPPLER ECHOGRAPHY; ENDOTHELIUM CELL; EPITHELIZATION; GRAFT PATENCY; HISTOLOGY; INTIMA; MALE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCANNING ELECTRON MICROSCOPY;

ANIMALS; ANTICHOLESTEREMIC AGENTS; AORTA, ABDOMINAL; BLOOD VESSEL PROSTHESIS; CELL ADHESION; CELL MOVEMENT; DOGS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; GRAFT OCCLUSION, VASCULAR; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MICROSCOPY, ELECTRON, SCANNING; NITRIC OXIDE SYNTHASE; POLYTETRAFLUOROETHYLENE; POSTOPERATIVE CARE; PROSTHESIS DESIGN; PROSTHESIS FITTING; PYRROLES; STEM CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR PATENCY;

EID: 77954073652     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319709356422     Document Type: Article

References (47)

1. Klinkert P., Schepers A., Burger DH, van Bockel JH, Breslau PJ Vein versus polytetrafluoroethylene in above-knee femoropopliteal bypass grafting: five-year results of a randomized controlled trial. J Vasc Surg. 2003; 37 (1). 149-155.
2. Bordenave L., Menu P., Baquey C. Developments towards tissue-engineered, small-diameter arterial substitutes. Expert Rev Med Devices. 2008; 5 (3). 337-347.
3. Sayers RD, Raptis S., Berce M., Miller JH Long-term results of femorotibial bypass with vein or polytetrafluoroethylene. Br J Surg. 1998; 85 (7). 934-938.
4. Ritter EF, Fata MM, Rudner AM, Klitzman B. Heparin bonding increases patency of long microvascular prostheses. Plast Reconstr Surg. 1998; 101 (1). 142-146.
5. Gosselin C., Vorp DA, Warty V., et al. ePTFE coating with fibrin glue, FGF-1, and heparin: Effect on retention of seeded endothelial cells. J Surg Res. 1996; 60 (2). 327-332.
6. Herring MB Endothelial cell seeding. J Vasc Surg. 1991; 13 (5). 731-732.
7. Conklin BS, Wu H., Lin PH, Lumsden AB, Chen C. Basic fibroblast growth factor coating and endothelial cell seeding of a decellularized heparin-coated vascular graft. Artif Organs. 2004; 28 (7). 668-675.
8. Cardinal KO, Bonnema GT, Hofer H., Barton JK, Williams SK Tissue-engineered vascular grafts as in vitro blood vessel mimics for the evaluation of endothelialization of intravascular devices. Tissue Eng. 2006; 12 (12). 3431-3438.
9. Cho SW, Lim JE, Chu HS, et al. Enhancement of in vivo endothelialization of tissue-engineered vascular grafts by granulocyte colony-stimulating factor. J Biomed Mater Res A. 2006; 76 (2). 252-263.
10. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995; 332 (8). 481-487.
11. Boodhwani M., Nakai Y., Voisine P., et al. High-dose atorvastatin improves hypercholesterolemic coronary endothelial dysfunction without improving the angiogenic response. Circulation. 2006; 114 (1 suppl). 402-408.
12. Rioufol G., Gilard M., Finet G., Ginon I., Boschat J., André-Fouët X. Evolution of spontaneous atherosclerotic plaque rupture with medical therapy: long-term follow-up with intravascular ultrasound. Circulation. 2004; 110 (18). 2875-2880.
13. Di Sciascio G., Patti G., Pasceri V., Gaspardone A., Colonna G., Montinaro A. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol. 2009; 54 (6). 558-565.
14. Briguori C., Visconti G., Focaccio A., et al. Novel approaches for preventing or limiting events (Naples) II Trial impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol. 2009. [Epub ahead of print].
15. Tousoulis D., Andreou I., Antoniades C., Tentolouris C., Stefanadis C. Role of inflammation and oxidative stress in endothelial progenitor cell function and mobilization: Therapeutic implications for cardiovascular diseases. Atherosclerosis. 2008; 201 (2). 236-247.
16. Paraskevas KI, Liapis CD, Hamilton G., Mikhailidis DP Are statins an option in the management of abdominal aortic aneurysms ? Vasc Endovascular Surg. 2008; 42 (2). 128-134.
17. Abbruzzese TA, Havens J., Belkin M., et al. Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. J Vasc Surg. 2004; 39 (6). 1178-1185.
18. Christenson JT Preoperative lipid control with simvastatin reduces the risk for graft failure already 1 year after myocardial revascularization. Cardiovasc Surg. 2001; 9 (1). 33-43.
19. Llevadot J., Murasawa S., Kureishi Y., et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest. 2001; 108 (3). 399-405.
20. Dimmeler S., Aicher A., Vasa M., et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the pi 3-kinase/akt pathway. J Clin Invest. 2001; 108 (3). 391-397.
21. Scott SM, Barth MG, Gaddy LR, Ahl ET Jr. The role of circulating cells in the healing of vascular prostheses. J Vasc Surg. 1994; 19 (4). 585-593.
22. Lahtinen M., Blomberg P., Baliulis G., Carlsson F., Khamis H., Zemgulis V. In vivo h-VEGF165 gene transfer improves early endothelialization and patency in synthetic vascular grafts. Eur J Cardiothorac Surg. 2007; 31 (3). 383-390.
23. Unver A., Perez M., Orellana N., Huang H., Rikihisa Y. Molecular and antigenic comparison of ehrlichia canis isolates from dogs, ticks, and a human in venezuela. J Clin Microbiol. 2001; 39 (8). 2788-2793.
24. Kusuyama T., Omura T., Nishiya D., et al. The effects of HMGCoA reductase inhibitor on vascular progenitor cells. J Pharmacol Sci. 2006; 101 (4). 344-349. (Pubitemid 44285183)
25. Rehman J., Li J., Orschell CM, March KL Peripheral blood "Endothelial progenitor cells" are derived from monocyte/ macrophages and secrete angiogenic growth factors. Circulation. 2003; 107 (8). 1164-1169.
26. Kaushal S., Amiel GE, Guleserian KJ, et al. Functional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo. Nat Med. 2001; 7 (9). 1035-1040.
27. Greisler HP Arterial regeneration over absorbable prostheses. Arch Surg. 1982; 117 (11). 1425-1431.
28. Pasquinelli G., Freyrie A., Preda P., Curti T., D'Addato M., Laschi R. Healing of prosthetic arterial grafts. Scanning Microsc. 1990; 4 (2). 351-362.
29. Zhang Z., Wang Z., Liu S., Kodama M. Pore size, tissue ingrowth, and endothelialization of small-diameter microporous polyurethane vascular prostheses. Biomaterials. 2004; 25 (1). 177-187.
30. Asahara T., Murohara T., Sullivan A., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997; 275 (5302). 964-967.
31. Cho SW, Lim SH, Kim IK, et al. Small-diameter blood vessels engineered with bone marrow-derived cells. Ann Surg. 2005; 241 (3). 506-515.
32. Werner N., Priller J., Laufs U., et al. Bone marrow-derived progenitor cells modulate vascular re-endothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler Thromb Vasc Biol. 2002; 22 (10). 1567-1572.
33. Crombez M., Chevallier P., Gaudreault RC, Petitclerc E., Mantovani D., Laroche G. Improving arterial prosthesis neo-endothelialization: Application of a proactive VEGF construct onto PTFE surfaces. Biomaterials. 2005; 26 (35). 7402-7409.
34. Randone B., Cavallaro G., Polistena A., et al. Dual role of VEGF in pretreated experimental EPTFE arterial grafts. J Surg Res. 2005; 127 (2). 70-79.
35. Li X., Xu B. HMG-CoA reductase inhibitor regulates endothelial progenitor function through the phosphatidylinositol 3'-kinase/akt signal transduction pathway. Appl Biochem Biotechnol. 2009; 157 (3). 545-553.
36. Ishida A., Wu MH, Shi Q., et al. Dynamic changes of smooth muscle and endothelial markers in the early healing process of dacron vascular grafts in the dog, using RT-PCR. Int J Angiol. 2000; 9 (2). 107-110.
37. Uchida C., Haas TL Evolving strategies in manipulating VEGF/ VEGFR signaling for the promotion of angiogenesis in ischemic muscle. Curr Pharm Des. 2009; 15 (4). 411-421.
38. Payne TR, Oshima H., Okada M., et al. A relationship between vascular endothelial growth factor, angiogenesis, and cardiac repair after muscle stem cell transplantation into ischemic hearts. J Am Coll Cardiol. 2007; 50 (17). 1677-1684.
39. Nishimoto-Hazuku A., Hirase T., Ide N., et al. Simvastatin stimulates vascular endothelial growth factor production by hypoxia-inducible factor-1 alpha upregulation in endothelial cells. J Cardiovasc Pharmacol. 2008; 51 (3). 267-273.
40. Wu H., Lu D., Jiang H., et al. Simvastatin-mediated upregulation of VEGF and BDNF, activation of the pi3k/ akt pathway, and increase of neurogenesis are associated with therapeutic improvement after traumatic brain injury. J Neurotrauma. 2008; 25 (2). 130-139.
41. Rikitake Y., Liao JK Rho GTPases, statins, and nitric oxide. Circ Res. 2005; 97 (12). 1232-1235.
42. Landmesser U., Engberding N., Bahlmann FH, et al. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation. 2004; 110 (14). 1933-1939.
43. Gonzalez-Fernandez F., Jimenez A., Lopez-Blaya A., et al. Cerivastatin prevents tumor necrosis factor-alpha-induced downregulation of endothelial nitric oxide synthase: role of endothelial cytosolic proteins. Atherosclerosis. 2001; 155 (1). 61-70.
44. Urbich C., Dernbach E., Zeiher AM, Dimmeler S. Double-edged role of statins in angiogenesis signaling. Circ Res. 2002; 90 (6). 737-744.
45. Ariyoshi H., Okuyama M., Okahara K., et al. Expanded polytetrafluoroethylene (ePTFE) vascular graft loses its thrombogenicity six months after implantation. Thromb Res. 1997; 88 (5). 427-433.
46. Fatourou EM, Paraskevas KI, Seifalian AM, Hamilton G., Mikhailidis DP The role of established and emerging risk factors in peripheral vascular graft occlusion. Expert Opin Pharmacother. 2007; 8 (7). 901-911.
47. Laufs U. Beyond lipid-lowering: effects of statins on endothelial nitric oxide. Eur J Clin Pharmacol. 2003; 58 (11). 719-731.